Doxorubicin liposomal - Celsion Corporation

Drug Profile

Doxorubicin liposomal - Celsion Corporation

Alternative Names: Liposome encapsulated doxorubicin; LTLD; LTSDEL; Lyso-thermosensitive liposomal doxorubicin; ThermoDox

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Celsion Corporation
  • Developer Brigham and Womens Hospital; Celsion Corporation; Focused Ultrasound Foundation; Harvard Medical School; University of Oxford
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II Breast cancer; Liver metastases
  • Preclinical Bladder cancer; Brain cancer; Glioblastoma; Pancreatic cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 13 Apr 2017 Preclinical trials in Bladder cancer in USA (IV)
  • 13 Apr 2017 Pharmacodynamics data from preclinical studies in Bladder cancer released by Celsion corporation
  • 18 Jan 2017 Celsion receives patent allowance for ThermoDox® in USA and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top